Kansai Nerolac Paints Limited
Quality (52/100) does the heavy lifting; valuation (27/100) is the drag.
Fair valueOur blended model reads Kansai Nerolac Paints Limited as a Sell at 38/100. At ₹196.74 it trades above our blended DCF and relative-multiples fair value of ₹155.31, about 21% downside to that estimate — we read it as overvalued by 21%. On 29.4x trailing earnings it sits pricier than the Basic Materials median of about 22.2x. The price is about 22% below its 52-week high of ₹253.83 and 25% above the low of ₹157.2. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 5/9. The average analyst target of ₹246.24 implies about 25% upside across 17 analysts. It clears 5 of 13 investability checks, with durability 52, valuation 40 and momentum 28 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹124.25.
Analyst views
1-year price
EOD · 2026-07-3152-week range
-22.49% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Sell38Piotroski F-score 5/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: 8.8%
- Pass: Low debt (D/E < 0.5): 0.05x
- Pass: Positive free cash flow
- Fail: Revenue growth > 10%: 8%
- Pass: Earnings growing: 4%
- Fail: Net margin ≥ 10%: 7.3%
- Pass: Current ratio > 1.5: 3.48
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Fail: Above 200-day average
- Fail: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 7.59
- Fail: Piotroski ≥ 7: 5/9
Quarterly results
Annual financials
Shareholding
- Promoter75.1%
- Institutions11.6%
- Public & other13.3%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Financially solid — Altman Z 7.59.
Bear case
Weaknesses
- Price below its 200-day moving average (downtrend).
Threats
- Trades ~21% above our estimated fair value.
About Kansai Nerolac Paints Limited
Kansai Nerolac Paints Limited engages in the manufacture and supply paints, varnishes, enamels, and lacquers in India. It provides interior and exterior wall paints, wood coatings, metal enamel paints, and ancillary paints, as well as adhesives and waterproofing products; interior textures; general industrial, powder, coil, automotive, auto refinish, and floor coatings; wood finishes, waterproofing solutions, and construction chemicals; and decorative and soldier paints. The
Kansai Nerolac Paints Limited — frequently asked questions
Is Kansai Nerolac Paints Limited a buy, hold or sell?
StocksWizard currently rates Kansai Nerolac Paints Limited (KANSAINER) a Sell, based on a blended score of 38/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Kansai Nerolac Paints Limited's fair value?
Our blended DCF and relative-valuation model estimates Kansai Nerolac Paints Limited's fair value at about ₹155.31, versus a current price of ₹196.74 — roughly 21% downside. On that basis the stock looks overvalued by 21%.
Is Kansai Nerolac Paints Limited financially healthy?
Kansai Nerolac Paints Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 5/9.
How has Kansai Nerolac Paints Limited's share price performed?
Kansai Nerolac Paints Limited is up 3% over three months, and last traded at ₹196.74. Past performance doesn't predict future returns.
More in Basic Materials
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.